NMRA / Neumora Therapeutics, Inc. - Pengajuan SECLaporan Tahunan, Pernyataan Proksi

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2025 Neumora Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41802 84-4367680 (State or Other Jurisdiction of Incorporation) (Commiss

Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected i

Exhibit 99.1 Neumora Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Update Initiated Phase 1 single-ascending dose/multiple-ascending dose (SAD/MAD) study with M4 positive allosteric modulator (PAM) NMRA-861, with data expected in the first quarter of 2026 Announces prioritization of obesity as lead indication for NMRA-215, a highly brain-penetrant NLRP3 inhibitor

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents 0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41802 NEUMORA THERAPEUTICS, INC.

Loan and Security Agreement, dated May 9, 2025, by and among the Registrant, K2 HealthVentures LLC, as lender and administrative agent for the lenders from time to time party thereto, and Ankura Trust Company, LLC, as collateral trustee.

Exhibit 10.1 CERTAIN INFORMATION IDENTIFIED BY “[***]” HAS BEEN EXCLUDED FROM THE EXHIBIT BECAUSE IT IS BOTH NOT MATERIAL AND IS THE TYPE OF INFORMATION THAT THE REGISTRANT TREATS AS PRIVATE OR CONFIDENTIAL. LOAN AND SECURITY AGREEMENT This LOAN AND SECURITY AGREEMENT (as amended, restated, supplemented or otherwise modified from time to time, this “Agreement”) dated as of May 9, 2025 (the “Closin

Amended and Restated Non-Employee Director Compensation Program.

EXHIBIT 10.2 NEUMORA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended through March 24, 2025) This Neumora Therapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program, as amended herein (this “Program”), has been adopted under the Company’s 2023 Incentive Award Plan (the “Plan”) and shall be effective as of March 24, 2025 (the “Effective Date”). Capitaliz

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 28, 2025 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Commission

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 14, 2025 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in Ma

Exhibit 99.1 Neumora Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update On track to report topline data from NMRA-511 in Alzheimer’s disease agitation around the end of 2025 Resumed enrollment for KOASTAL-3 and -2 studies in March 2025; anticipate reporting topline major depressive disorder data from KOASTAL-3 in the first quarter of 2026 and -2 in the second qu

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents 0 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2025 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41802 NEUMORA THERAPEUTICS, INC.

FORM 8-K Item 2.02 Results of Operations and Financial Condition. Item 9.01 Financial Statements and Exhibits.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2025 Neumora Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41802 84-4367680 (State or Other Jurisdiction of Incorporation) (Commission

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 Neumora Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41802 84-4367680 (State or Other Jurisdiction of Incorporation) (Com

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☒ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

Executive Employment Agreement, dated as of February 14, 2025, by and between the Registrant and Bill Aurora, Pharm.D.

Exhibit 10.19 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Bill Aurora, Pharm.D. (“Executive” and, together with the Company, the “Parties”) effective as of February 14, 2025 (the “Effective Date”). This Agreement supersedes in its entire

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Neumora Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered (1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock, $0.00

As filed with the Securities and Exchange Commission on March 3, 2025

Table of Contents As filed with the Securities and Exchange Commission on March 3, 2025 Registration No.

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Neumora Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registratio

Executive Employment Agreement, dated as of February 14, 2025, by and between the Registrant and Michael Milligan.

Exhibit 10.17 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Michael Milligan (“Executive” and, together with the Company, the “Parties”) effective as of February 14, 2025 (the “Effective Date”). WHEREAS, the Company desires to assure itsel

Separation Agreement, dated February 15, 2025, by and between the Registrant and Henry O. Gosebruch.

Exhibit 10.14 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between Henry O. Gosebruch (“Executive”) and Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth day following the date Executive signs this Agreement, which shall in no event be prior to the Separation Date (the date this Agreement becomes effective and irrevoca

Executive Employment Agreement, dated as of February 14, 2025, by and between the Registrant and Joshua Pinto, Ph.D.

Exhibit 10.18 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Joshua Pinto, Ph.D. (“Executive” and, together with the Company, the “Parties”) effective as of February 14, 2025 (the “Effective Date”). This Agreement supersedes in its entirety

Executive Employment Agreement, dated as of August 31, 2023, by and between the Registrant and Robert Lenz, M.D., Ph.D.

Exhibit 10.20 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Robert Lenz, M.D., Ph.D. (“Executive” and, together with the Company, the “Parties”) effective as of August 31, 2023 (the “Effective Date”). WHEREAS, the Company desires to assure

As filed with the Securities and Exchange Commission on March 3, 2025

As filed with the Securities and Exchange Commission on March 3, 2025 Registration No.

Insider Trading Policy

Exhibit 19.1 POLICY Title: Insider Trading Policy and Procedures Document Number: POL-00026 Version: 3.0 Effective Date: 1.0 PURPOSE Federal and state laws prohibit trading in the Securities of a company while in possession of material nonpublic information and in breach of a duty of trust or confidence. These laws also prohibit anyone who is aware of material nonpublic information from providing

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K

Table of Contents thatin03ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-41802 NEUMORA THERAPEUTICS, INC.

Executive Employment Agreement, effective as of February 14, 2025, by and between the Registrant and Paul L. Berns.

Exhibit 10.12 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Paul L. Berns (“Executive” and, together with the Company, the “Parties”) effective as of February 14, 2025 (the “Effective Date”). This Agreement supersedes in its entirety the

Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and

Exhibit 99.1 Neumora Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Business Update KOASTAL-2 and -3 studies optimized based on learnings from KOASTAL-1; topline data expected from KOASTAL-3 in the first quarter of 2026 and -2 in the second quarter of 2026 Topline data from NMRA-511 in Alzheimer’s disease agitation expected by the end of 2025 Expect to progre

As filed with the Securities and Exchange Commission on March 3, 2025

Table of Contents As filed with the Securities and Exchange Commission on March 3, 2025 Registration No.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 03, 2025 Neumora Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41802 84-4367680 (State or Other Jurisdiction of Incorporation) (Commissi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A Amendment No. 1 CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of inc

Neumora Therapeutics Announces Leadership Transition Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board Joshua Pinto, Ph.D. to serve as president Bill Aurora, Pharm.D. to serve

Exhibit 99.1 Neumora Therapeutics Announces Leadership Transition Paul L. Berns, executive chair of Neumora Board of Directors, to serve as chief executive officer and chairman of the Board Joshua Pinto, Ph.D. to serve as president Bill Aurora, Pharm.D. to serve as chief operating and development officer; Michael Milligan to serve as chief financial officer Neumora to host conference call on March

Regulation FD Disclosure

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 13, 2025 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 NEUMORA THERAPEU

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 13, 2025 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Commis

Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention

Redefining Neuroscience Drug Development January 2025 Exhibit 99.1 Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by bringing forward the next generation

Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total scor

EX-99.1 2 d859264dex991.htm EX-99.1 Exhibit 99.1 Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total score compared to placebo Navacaprant showed an efficacy signal in female participants; Company plans to

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 NEUMORA THERAPEUT

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 2, 2025 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Commiss

NMRA / Neumora Therapeutics, Inc. / ARCH Venture Fund XII, L.P. - ARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS -- SCH 13D/A(#2) Activist Investment

SC 13D/A 1 arch-sch13d18910.htm ARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS - SCH 13D/A(#2) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 2)* Neumora Therapeutics, Inc. (Name of Issuer)      Common Stock, $0.0001 par value     (Title of Class of Securities)     640979 100    (CUSIP Number) Mark M

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents 03ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41802 NEUMORA THERAPEUTICS, INC.

NMRA / Neumora Therapeutics, Inc. / SOFTBANK GROUP CORP Passive Investment

SC 13G 1 formsc13g.htm United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Neumora Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 p

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 12, 2024 Neumora Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41802 84-4367680 (State or Other Jurisdiction of Incorporation) (Commi

Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of

EXHIBIT 99.1 Neumora Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected around the end of 2024; KOASTAL-2 and KOASTAL-3 topline data expected in the first half of 2025 Ongoing clinical studies evaluating navacaprant in bipolar depression and NMRA-511 in Alzheimer’s disease agitation with data expec

Form of Indenture

Exhibit 4.3 NEUMORA THERAPEUTICS, INC. INDENTURE Dated as of , 20 [] Trustee TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND INCORPORATION BY REFERENCE 1 Section 1.1. Definitions 1 Section 1.2. Other Definitions 4 Section 1.3. Incorporation by Reference of Trust Indenture Act 5 Section 1.4. Rules of Construction 5 ARTICLE II. THE SECURITIES 6 Section 2.1. Issuable in Series 6 Section 2.2. Establ

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables Form S-3 (Form Type) Neumora Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum  Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee (5) Newly Registered Secu

As filed with the Securities and Exchange Commission on October 1, 2024

Table of Contents As filed with the Securities and Exchange Commission on October 1, 2024 Registration No.

Sales Agreement, dated October 1, 2024, by and between Neumora Therapeutics, Inc. and Leerink Partners LLC

Exhibit 1.2 Neumora Therapeutics, Inc. Shares of Common Stock ($0.0001 par value per share) SALES AGREEMENT October 1, 2024 LEERINK PARTNERS LLC 1301 Avenue of the Americas, 5th Floor New York, New York 10019 Ladies and Gentlemen: Neumora Therapeutics, a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows: 1. Issuance

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 06, 2024 Neumora Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41802 84-4367680 (State or Other Jurisdiction of Incorporation) (Commiss

Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected in fourth quarter of 2024 Progressing clinical studies in MDD, bipolar depression and Alz

EXHIBIT 99.1 Neumora Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update Phase 3 data from KOASTAL-1 study of navacaprant in MDD expected in fourth quarter of 2024 Progressing clinical studies in MDD, bipolar depression and Alzheimer’s disease agitation, providing opportunity for multiple value-creating catalysts over next 18 months Strong financial position wit

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents 03ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41802 NEUMORA THERAPEUTICS, INC.

Second Amendment to License Agreement, dated May 17, 2024, by and between the Registrant and Vanderbilt University.

Exhibit 10.1 SECOND AMENDMENT TO LICENSE AGREEMENT This Second Amendment (this “Amendment”) is effective as of May 10, 2024 (the “Second Amendment Date”) and is made to that certain License Agreement by and between Vanderbilt University, a not-for-profit corporation, organized and existing under the laws of the state of Tennessee (“Vanderbilt”), and Neumora Therapeutics, Inc., a corporation organi

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 13, 2024 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Commissio

Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study i

EXHIBIT 99.1 Neumora Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update On-track to report topline Phase 3 data from KOASTAL-1 study with navacaprant in MDD; guidance narrowed to fourth quarter of 2024 Multiple clinical study initiations planned in second quarter of 2024, including Phase 2 study in bipolar depression with navacaprant and Phase 1b study in Alzhei

Financial Statements and Exhibits, Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 07, 2024 Neumora Therapeutics, Inc. (Exact name of Registrant as Specified in Its Charter) Delaware 001-41802 84-4367680 (State or Other Jurisdiction of Incorporation) (Commission

Non-Employee Director Compensation Program.

Exhibit 10.1 NEUMORA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM (as amended through March 13, 2024) This Neumora Therapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program, as amended herein (this “Program”), has been adopted under the Company’s 2023 Incentive Award Plan (the “Plan”) and shall be effective as of March 13, 2024 (the “Effective Date”). Capitaliz

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents 03ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41802 NEUMORA THERAPEUTICS, INC.

RBNC Therapeutics, Inc. Milestone Carveout Plan

Exhibit 10.2 RBNC THerapeutics, Inc. MILESTONE CARVEOUT Plan 1. Purpose. RBNC Therapeutics, Inc., a Delaware corporation (the “Company”), entered into that certain Agreement and Plan of Merger dated as of June 1, 2020 with BlackThorn Therapeutics, Inc. (“BlackThorn”) and Fortis Advisors LLC (the “Stockholders’ Representative”, such agreement the “Merger Agreement” and such transaction thereunder t

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☒ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. )

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 (Amendment No. ) Filed by the Registrant ☒ Filed by a party other than the Registrant ☐ Check the appropriate box: ☐ Preliminary Proxy Statement ☐ Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2)) ☐ Defin

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 NEUMORA THERAPEUTI

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 15, 2024 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Commissi

Form 10-K

Table of Contents 03ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number: 001-41802 NEUMORA THERAPEUTICS, INC.

Clawback Policy

Exhibit 97.1 NEUMORA THERAPEUTICS, INC. POLICY FOR RECOVERY OF ERRONEOUSLY AWARDED COMPENSATION Neumora Therapeutics, Inc. (the “Company”) has adopted this Policy for Recovery of Erroneously Awarded Compensation (the “Policy”), effective as of September 14, 2023 (the “Effective Date”). Capitalized terms used in this Policy but not otherwise defined herein are defined in Section 11. 1. Persons Subj

As filed with the Securities and Exchange Commission on March 7, 2024

As filed with the Securities and Exchange Commission on March 7, 2024 Registration No.

Executive Employment Agreement, dated as of November 13, 2023, by and between the Registrant and Jason Duncan.

Exhibit 10.22 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Jason Duncan (“Executive” and, together with the Company, the “Parties”) effective as of November 13, 2023 (the “Effective Date”). WHEREAS, the Company desires to assure itself of

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2024 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Commissio

Filing Fee Table.

Exhibit 107.1 Calculation of Filing Fee Table Form S-8 (Form Type) Neumora Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type  Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity  Common stock, $0.0

Executive Employment Agreement, dated as of January 1, 2023, by and between the Registrant and Carol Y. Suh.

Exhibit 10.23 NEUMORA THERAPEUTICS, INC. AMENDED AND RESTATED EXECUTIVE EMPLOYMENT AGREEMENT This Amended and Restated Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Carol Y. Suh (“Executive” and, together with the Company, the “Parties”) effective as of January 1, 2023 (t

Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NM

Exhibit 99.1 Neumora Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Update On-track to report topline Phase 3 data from the KOASTAL-1 study with navacaprant in MDD in the second half of 2024 and Phase 1 data with NMRA-266 in healthy adult participants mid-2024 Strong financial position with $463.8 million in cash, cash equivalents and marketable secu

NMRA / Neumora Therapeutics, Inc. / BERNS PAUL L - SC 13G Passive Investment

SC 13G 1 d767902dsc13g.htm SC 13G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Neumora Therapeutics, Inc. (Name of Issuer) Common Stock par value $0.0001 per share (Title of Class of Securities) 640979100 (CUSIP Number) December 31, 2023 (Date of Event which Requires Filing of this Statement) Check

AGREEMENT

EX-99.1 2 d767902dex991.htm EX-99.1 CUSIP No. 640979100 13G Page 6 of 6 Pages Exhibit 1 AGREEMENT Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Neumora Therapeutics, Inc. This

Joint Filing Agreement.

EX-99 2 ex99.htm Exhibit 99 JOINT FILING AGREEMENT In accordance with Rule 13d-1(k)(1) promulgated under the Securities Exchange Act of 1934, as amended, the undersigned hereby agree that they are jointly filing this statement on Schedule 13G. Each of them is responsible for the timely filing of such statement and any amendments thereto, and for the completeness and accuracy of the information con

NMRA / Neumora Therapeutics, Inc. / SOFTBANK GROUP CORP Passive Investment

United States Securities and Exchange Commission Washington, D.C. 20549 Schedule 13G (Rule 13d-102) Information to be Included in Statements Filed Pursuant to § 240.13d-1(b), (c) and (d) and Amendments Thereto Filed Pursuant to § 240.13d-2 UNDER THE SECURITIES EXCHANGE ACT OF 1934 (Amendment No. )* Neumora Therapeutics, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Clas

Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention

Exhibit 99.1 J.P. Morgan Healthcare Conference January 2024 Important Disclosures This presentation contains forward-looking statements about Neumora Therapeutics, Inc. (the “Company,” “we,” “us,” or “our”) within the meaning of the federal securities laws, including statements related to: Neumora’s intention to redefine neuroscience drug development by bringing forward the next generation of nove

Regulation FD Disclosure, Financial Statements and Exhibits

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 8, 2024 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Commiss

NMRA / Neumora Therapeutics Inc. / ARCH Venture Fund XII, L.P. - ARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS -- SCH 13D/A(#1) Activist Investment

SC 13D/A 1 arch-sch13d18782.htm ARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS - SCH 13D/A(#1) UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. 1)* Neumora Therapeutics, Inc. (Name of Issuer)      Common Stock, $0.0001 par value     (Title of Class of Securities)     640979 100    (CUSIP Number) Mark M

Financial Statements and Exhibits, Other Events

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 27, 2023 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Commi

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q

Table of Contents 3ROC UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-41802 NEUMORA THERAPEUTICS, INC.

Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Navacaprant Phase 3 KOASTAL program in major depressive disorder on track; planned initiation of Phase 2 bipolar depression trial in 1H24 Progressing NMRA-

Exhibit 99.1 Neumora Therapeutics Reports Third Quarter 2023 Financial Results and Provides Business Update Navacaprant Phase 3 KOASTAL program in major depressive disorder on track; planned initiation of Phase 2 bipolar depression trial in 1H24 Progressing NMRA-511 and NMRA-266 toward near-term clinical milestones and advancing multiple preclinical neuropsychiatric and neurodegeneration programs

Results of Operations and Financial Condition

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 1, 2023 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Commis

ARCH Venture Fund XII, L.P. - ARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS -- SCH 13D

SC 13D 1 arch-sch13d18764.htm ARCH VENTURE FUND XII, L.P. - NEUMORA THERAPEUTICS - SCH 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No.     )* Neumora Therapeutics, Inc. (Name of Issuer)      Common Stock, $0.0001 par value     (Title of Class of Securities)     640979 100    (CUSIP Number) Mark McDonn

AMGEN INC - SC 13D

SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. )* Neumora Therapeutics, Inc. (Name of Issuer) Common Stock (Title of Class of Securities) 640979100 (CUSIP Number) Jonathan P. Graham Executive Vice President and General Counsel and Secretary One Amgen Center Drive Thousand Oaks, CA 91320-1799 (805)

RBNC THERAPEUTICS, INC.

EX-3 Exhibit 3 RBNC THERAPEUTICS, INC. September 10, 2021 Amgen Inc. One Amgen Center Drive Thousand Oaks, California 91320 Attn: Re: Letter Agreement regarding the acquisition of shares of Series A-2 Preferred Stock by Amgen Inc. (“Amgen”, together with its Affiliates (as defined below), the “Investor”) of RBNC Therapeutics, Inc. (the “Company”) Ladies and Gentlemen: Reference is made to (i) that

September 22, 2022

EX-4 Exhibit 4 September 22, 2022 Neumora Therapeutics, Inc. 65 Grove Street Watertown, Massachusetts 02472 ATTENTION: Chief Executive Officer Re: Amendment to Letter Agreement Ladies and Gentlemen: Reference is made to that certain Letter Agreement, dated as of September 10, 2021, by and between Amgen Inc. (“Amgen”) and Neumora Therapeutics, Inc. (f/k/a RBNC Therapeutics, Inc.; the “Company”), re

Fee Table.

Exhibit 107.1 Calculation of Filing Fee Tables Form S-8 (Form Type) Neumora Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1—Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount to be Registered(1) Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Equity Common stock,

2023 Employee Stock Purchase Plan.

Exhibit 99.4 NEUMORA THERAPEUTICS, INC. 2023 EMPLOYEE STOCK PURCHASE PLAN ARTICLE 1 PURPOSE The Plan’s purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company, and to help such employees provide for their future security and to encourage them to remain in the employment of the Company and its Subsidiaries. The Plan consis

2023 Incentive Award Plan.

Exhibit 99.3(a) NEUMORA THERAPEUTICS, INC. 2023 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the Plan, the following words and phrase

BlackThorn Therapeutics, Inc. 2015 Equity Incentive Plan

Exhibit 99.1(a) BLACKTHORN THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better ali

As filed with the Securities and Exchange Commission on September 19, 2023

As filed with the Securities and Exchange Commission on September 19, 2023 Registration No.

Form of Stock Option Agreement under the BlackThorn Therapeutics, Inc. 2015 Equity Incentive Plan.

Exhibit 99.1(b) BLACKTHORN THERAPEUTICS, INC. 2015 EQUITY INCENTIVE PLAN STOCK OPTION GRANT NOTICE AND STOCK OPTION AGREEMENT Blackthorn Therapeutics, Inc. (the “Company”), pursuant to its 2015 Equity Incentive Plan (the “Plan”), hereby grants to the participant set forth below (“Participant”), an option (the “Option”) to purchase the number of shares of the Company’s Common Stock (referred to her

Current Report

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 19, 2023 NEUMORA THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) Delaware 001-41802 84-4367680 (State or other jurisdiction of incorporation) (Comm

Amended and Restated Certificate of Incorporation, as amended, currently in effect.

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEUMORA THERAPEUTICS, INC. Neumora Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Neumora Therapeutics, Inc.. The Corporation was incorporated under the name RBNC The

Bylaws, as amended, currently in effect.

Exhibit 3.2 Amended and Restated Bylaws of Neumora Therapeutics, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting 2 2.5 Notice of Nominations for Election to t

14,710,000 Shares Common Stock

Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-274229 14,710,000 Shares Common Stock This is an initial public offering of shares of common stock of Neumora Therapeutics, Inc. We are offering 14,710,000 shares of our common stock. Prior to this offering, there has been no public market for our common stock. Our initial public offering price is $17.00 per share. Our common

Form 8-A

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-A FOR REGISTRATION OF CERTAIN CLASSES OF SECURITIES PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 Neumora Therapeutics, Inc. (Exact name of registrant as specified in its charter) Delaware 84-4367680 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification

[signature page follows]

September 12, 2023 United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.

Neumora Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown, Massachusetts 02472

Neumora Therapeutics, Inc. 490 Arsenal Way, Suite 200 Watertown, Massachusetts 02472 September 12, 2023 VIA EDGAR AND E-MAIL United States Securities and Exchange Commission Division of Corporation Finance Office of Life Sciences 100 F Street, N.E. Washington, D.C. 20549-6010 Attention: Eric Atallah Al Pavot Daniel Crawford Laura Crotty Re: Neumora Therapeutics, Inc. Registration Statement on Form

Form of Indemnification and Advancement Agreement for directors and officers.

Exhibit 10.13 INDEMNIFICATION AND ADVANCEMENT AGREEMENT This Indemnification and Advancement Agreement (“Agreement”) is made as of , 20 by and between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and , [a member of the Board of Directors/an officer/an employee] of the Company (“Indemnitee”). This Agreement supersedes and replaces any and all previous Agreements between the C

Exhibit 6- Form of Lock-Up Agreement (incorporated by reference to the Form of Underwriting Agreement filed as Exhibit 1.1 the Issuer’s Registration Statement on Form S-1/A (File No. 333-274229), as filed with the Securities and Exchange Commission on September 11, 2023).

EX-1.1 Exhibit 1.1 Neumora Therapeutics, Inc. [●] Shares of Common Stock, par value $0.0001 per share Underwriting Agreement [●], 2023 J.P. Morgan Securities LLC BofA Securities, Inc. As Representatives of the several Underwriters listed in Schedule 1 hereto c/o J.P. Morgan Securities LLC 383 Madison Avenue New York, NY 10179 c/o BofA Securities, Inc. One Bryant Park New York, NY 10036 Ladies and

First Amendment to Exclusive License Agreement for GCase, dated June 14, 2022, by and between the Registrant and Amgen, Inc.

Exhibit 10.4(b) AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT This AMENDMENT NO. 1 TO EXCLUSIVE LICENSE AGREEMENT (this “Amendment”) is made as of June 14, 2022 (the “Amendment Effective Date”), by and between Amgen Inc., with its principal offices at One Amgen Center Drive, Thousand Oaks, California 91320 (“Amgen”) and Neumora Therapeutics, Inc. with its principal offices at 65 Grove Street, Wat

Form of Common Stock Certificate.

Exhibit 4.2 ZQ|CERT#|COY|CLS|RGSTRY|ACCT#|TRANSTYPE|RUN#|TRANS# COMMON STOCK PAR VALUE $.01 COMMON STOCK Certificate Number ZQ00000000 NeumoraTM NEUMORA THERAPEUTICS, INC. INCORPORATED UNDER THE LAWS OF THE STATE OF DELAWARE THIS CERTIFIES THAT Shares * * 000000 ****************** * * * 000000 ***************** **** 000000 **************** ***** 000000 *************** ****** 000000 **************

Non-Employee Director Compensation Program.

Exhibit 10.21 NEUMORA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Neumora Therapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2023 Incentive Award Plan (the “Plan”) and shall be effective upon the closing of the Company’s initial public offering of its common stock (the “IPO”). Capitalized terms

As filed with the Securities and Exchange Commission on September 11, 2023.

S-1/A Table of Contents As filed with the Securities and Exchange Commission on September 11, 2023.

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables Form S-1 (Form Type) Neumora Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee(3) Fees to be Paid Equity

* * *

505 Montgomery Street, Suite 2000 San Francisco, California 94111-6538 Tel: +1.415.391.0600 Fax: +1.415.395.8095 www.lw.com FIRM / AFFILIATE OFFICES August 25, 2023 Austin Beijing Boston Brussels Century City Chicago Dubai Düsseldorf Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan Munich New York Orange County Paris Riyadh San Diego San Francisco Seoul Shanghai Silicon Valley S

Employment Agreement by and between the Registrant and Joshua Pinto, Ph.D.

Exhibit 10.11 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Joshua Pinto (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supers

Form of Amended and Restated Certificate of Incorporation, to be in effect immediately prior to the completion of this offering

Exhibit 3.2 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEUMORA THERAPEUTICS, INC. Neumora Therapeutics, Inc. (the “Corporation”), a corporation organized and existing under the General Corporation Law of the State of Delaware (the “DGCL”), does hereby certify as follows: 1. The name of the Corporation is Neumora Therapeutics, Inc.. The Corporation was incorporated under the name RBNC The

Agreement and Plan of Merger, dated November 24, 2020, by and among the Registrant, Alairion Merger Sub I, Inc, Alairion Merger Sub II, LLC, Alairion, Inc. and John F. Dee.

Exhibit 2.2 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. AGREEMENT AND PLAN OF MERGER by and among RBNC THERAPEUTICS, INC., ALAIRION MERGER SUB I, INC., ALAIRION MERGER SUB II, LLC, ALAIRION, INC. and JOHN F. DEE, solely in his capacity

Investors’ Rights Agreement, dated September 22, 2022, by and among the Registrant and the investors listed therein.

Exhibit 10.1 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT NEUMORA THERAPEUTICS, INC. September 22, 2022 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of September 22, 2022, by and among Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors in the Company’s Series B Pr

Bylaws, currently in effect

Exhibit 3.3 BYLAWS OF RBNC THERAPEUTICS, INC. (a Delaware corporation) Adopted as of January 16, 2020 TABLE OF CONTENTS Page ARTICLE I. IDENTIFICATION; OFFICES 1 SECTION 1. NAME 1 SECTION 2. PRINCIPAL AND BUSINESS OFFICES 1 SECTION 3. REGISTERED AGENT AND OFFICE 1 SECTION 4. CORPORATE RECORDS 1 ARTICLE II. STOCKHOLDERS 1 SECTION 1. ANNUAL MEETING 1 SECTION 2. SPECIAL MEETING 1 SECTION 3. PLACE OF

Agreement and Plan of Merger, dated June 1, 2020, by and among the Registrant, Berries Merger Sub, Inc, BlackThorn Therapeutics, Inc. and Fortis Advisors LLC.

Exhibit 2.1 [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. AGREEMENT AND PLAN OF MERGER by and among RBNC THERAPEUTICS, INC., BERRIES MERGER SUB, INC., BLACKTHORN THERAPEUTICS, INC. and Fortis Advisors LLC, solely in its capacity as the S

Executive Chairman Agreement, dated as of July 3, 2023, by and between the Registrant and Paul L. Berns

Exhibit 10.19 NEUMORA THERAPEUTICS, INC. EXECUTIVE CHAIRMAN AGREEMENT THIS EXECUTIVE CHAIRMAN AGREEMENT (this “Agreement”) is made and entered into effective as of July 3, 2023 (the “Effective Date”), by and between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Paul L. Berns, an individual (the “Chairman”). 1. Services. 1.1 Executive Chairman. For so long as the Board of

Consulting Agreement, dated as of May 20, 2023, by and between the Registrant and John Dunlop, Ph.D.

Exhibit 10.18 NEUMORA THERAPEUTICS, INC. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into effective as of May 20, 2023 (the “Effective Date”) by and between NEUMORA THERAPEUTICS, INC. (“Neumora” or the “Company”), and John Dunlop (“Consultant”). Neumora desires to retain Consultant as an independent contractor to perform consulting services for Neumora, and Consultant i

Separation Agreement by and between the Registrant and John Dunlop, Ph.D.

Exhibit 10.17 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between John Dunlop (“Executive”), and Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement, which, for the avoidance of doubt, shall not be prior to the Termination Date (as defined below), if not revoke

Form of Stock Option Grant Notice and Stock Option Agreement under the 2023 Incentive Award Plan.

Exhibit 10.7(b) NEUMORA THERAPEUTICS, INC. 2023 INCENTIVE AWARD PLAN STOCK OPTION GRANT NOTICE Neumora Therapeutics, Inc., a Delaware corporation, (the “Company”), pursuant to its 2023 Incentive Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an option to purchase the number of shares of the Company’s Common Stock (the “Shares

Form of Executive Employment Agreement for Chief Executive Officer

Exhibit 10.16 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [ ] (“Executive” and, together with the Company, the “Parties”) effective as of April , 2022 (the “Effective Date”). This Agreement supersedes in its

First Amendment to License Agreement, dated July 17, 2023, by and between the Registrant and Vanderbilt University.

Exhibit 10.14(b) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. FIRST AMENDMENT TO LICENSE AGREEMENT This First Amendment (this “Amendment”) is effective as of July 17, 2023 (the “Amendment Date”) and is made to that certain License Agree

Employee Stock Purchase Plan

Exhibit 10.8 NEUMORA THERAPEUTICS, INC. 2023 EMPLOYEE STOCK PURCHASE PLAN ARTICLE 1 PURPOSE The Plan’s purpose is to assist employees of the Company and its Designated Subsidiaries in acquiring a stock ownership interest in the Company, and to help such employees provide for their future security and to encourage them to remain in the employment of the Company and its Subsidiaries. The Plan consis

Form of Restricted Stock Purchase Agreement under the 2020 Equity Incentive Plan.

Exhibit 10.6(c) RBNC THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN RESTRICTED STOCK PURCHASE AGREEMENT Pursuant to the award summary tab (the “Grant Notice”) on the website to which this Restricted Stock Purchase Agreement (this “Agreement”) is associated, RBNC Therapeutics, Inc., a Delaware corporation (the “Company”), has granted to the holder set forth in the Grant Notice (the “Purchaser”) the

Form of Stock Option Agreement under the 2020 Equity Incentive Plan.

Exhibit 10.6(b) RBNC THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Pursuant to the option grant summary tab (“Grant Notice”) on the website to which this Stock Option Agreement (this “Agreement”) is associated, RBNC Therapeutics, Inc. (the “Company”) has granted to the option holder set forth in the Grant Notice (“Participant”) an option (the “Option”) under the Company’s 20

First Amendment to License Agreement, dated November 13, 2017, by and between BlackThorn Therapeutics, Inc. and Scripps Research Institute

Exhibit 10.5(b) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This First Amendment (“Amendment”) is entered into effective as of November 13, 2017 and is made to the EXCLUSIVE LICENSE AGREEM

Exclusive License Agreement for GCase, dated September 10, 2021, by and between the Registrant and Amgen Inc.

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

2023 Incentive Award Plan

Exhibit 10.7(a) NEUMORA THERAPEUTICS, INC. 2023 INCENTIVE AWARD PLAN ARTICLE I. PURPOSE The Plan’s purpose is to enhance the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing these individuals with equity ownership opportunities. ARTICLE II. DEFINITIONS As used in the Plan, the following words and phrase

Non-Employee Director Compensation Program

Exhibit 10.12 NEUMORA THERAPEUTICS, INC. NON-EMPLOYEE DIRECTOR COMPENSATION PROGRAM This Neumora Therapeutics, Inc. (the “Company”) Non-Employee Director Compensation Program (this “Program”) has been adopted under the Company’s 2023 Incentive Award Plan (the “Plan”) and shall be effective upon the closing of the Company’s initial public offering of its common stock (the “IPO”). Capitalized terms

As filed with the Securities and Exchange Commission on August 25, 2023.

Table of Contents As filed with the Securities and Exchange Commission on August 25, 2023.

Amended and Restated Certificate of Incorporation, as amended, currently in effect

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEUMORA THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Neumora Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. T

Form of Restricted Stock Unit Award Grant Notice and Restricted Stock Unit Award Agreement under the 2023 Incentive Award Plan.

Exhibit 10.7(c) NEUMORA THERAPEUTICS, INC. 2023 INCENTIVE AWARD PLAN RESTRICTED STOCK UNIT AWARD GRANT NOTICE Neumora Therapeutics, Inc., a Delaware corporation, (the “Company”), pursuant to its 2023 Incentive Award Plan, as may be amended from time to time (the “Plan”), hereby grants to the holder listed below (“Participant”), an award of restricted stock units (“Restricted Stock Units” or “RSUs”

2020 Equity Incentive Plan.

Exhibit 10.6(a) RBNC THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better aligning

Second Amendment to License Agreement, dated April 9, 2019, by and between BlackThorn Therapeutics, Inc. and Scripps Research Institute.

Exhibit 10.5(c) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This Second Amendment (“Amendment”) is entered into effective as of April 9, 2019 and is made to the EXCLUSIVE LICENSE AGREEMEN

Executive Employment Agreement, dated as of June 2, 2023, by and between the Registrant and Henry O. Gosebruch.

Exhibit 10.20 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Henry Gosebruch (“Executive” and, together with the Company, the “Parties”) this June 2, 2023 (the “Effective Date”). WHEREAS, the Company desires to assure itself of the service

Research Collaboration and License Agreement, dated September 10, 2021, by and between the Registrant and Amgen Inc.

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

Form of Executive Employment Agreement

Exhibit 10.15 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [] (“Executive” and, together with the Company, the “Parties”) effective as of April , 2022 (the “Effective Date”). This Agreement supersedes in its

License Agreement, dated February 10, 2022, by and between the Registrant and Vanderbilt University.

Exhibit 10.14(a) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. LICENSE AGREEMENT BETWEEN VANDERBILT UNIVERSITY AND NEUMORA THERAPEUTICS, INC. Table of Contents Article 1 DEFINITION OF TERMS 1 Article 2 GRANT 9 Article 3 FINANCIAL CONSIDE

Employment Agreement by and between the Registrant and John Dunlop, Ph.D.

Exhibit 10.10 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and John Dunlop (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement superse

Filing Fee Table

Exhibit 107.1 Calculation of Filing Fee Tables Form S-1 (Form Type) Neumora Therapeutics, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1)(2) Fee Rate Amount of Registration Fee Fees to be Paid Equity

Form of Amended and Restated Bylaws, to be in effect immediately prior to the completion of this offering

Exhibit 3.4 Amended and Restated Bylaws of Neumora Therapeutics, Inc. (a Delaware corporation) Table of Contents Page Article I - Corporate Offices 1 1.1 Registered Office 1 1.2 Other Offices 1 Article II - Meetings of Stockholders 1 2.1 Place of Meetings 1 2.2 Annual Meeting 1 2.3 Special Meeting 1 2.4 Notice of Business to be Brought before a Meeting 2 2.5 Notice of Nominations for Election to t

Employment Agreement by and between the Registrant and Paul L. Berns

Exhibit 10.9 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Paul Berns (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersede

License Agreement, dated November 23, 2015, by and between BlackThorn Therapeutics, Inc. and Scripps Research Institute.

Exhibit 10.5(a) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. LICENSE AGREEMENT This License Agreement is effective as of November 23, 2015 (the “Effective Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit pub

Exclusive License Agreement for CK1d, dated September 10, 2021, by and between the Registrant and Amgen Inc.

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

NEUMORA THERAPEUTICS, INC. EXECUTIVE CHAIRMAN AGREEMENT

Exhibit 10.20 NEUMORA THERAPEUTICS, INC. EXECUTIVE CHAIRMAN AGREEMENT THIS EXECUTIVE CHAIRMAN AGREEMENT (this “Agreement”) is made and entered into effective as of July 3, 2023 (the “Effective Date”), by and between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Paul L. Berns, an individual (the “Chairman”). 1. Services. 1.1 Executive Chairman. For so long as the Board of

Confidential Draft Submission No. 9 submitted to the Securities and Exchange Commission on August 8, 2023. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains st

Table of Contents Confidential Draft Submission No. 9 submitted to the Securities and Exchange Commission on August 8, 2023. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRA

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.21 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement”) is entered into between Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and Henry Gosebruch (“Executive” and, together with the Company, the “Parties”) this June 2, 2023 (the “Effective Date”). WHEREAS, the Company desires to assure itself of the service

NEUMORA THERAPEUTICS, INC. CONSULTING AGREEMENT

Exhibit 10.19 NEUMORA THERAPEUTICS, INC. CONSULTING AGREEMENT THIS CONSULTING AGREEMENT (“Agreement”) is entered into effective as of May 20, 2023 (the “Effective Date”) by and between NEUMORA THERAPEUTICS, INC. (“Neumora” or the “Company”), and John Dunlop (“Consultant”). Neumora desires to retain Consultant as an independent contractor to perform consulting services for Neumora, and Consultant i

SEPARATION AGREEMENT

Exhibit 10.18 SEPARATION AGREEMENT This Separation Agreement (the “Agreement”) by and between John Dunlop (“Executive”), and Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth (8th) day following the date Executive signs this Agreement, which, for the avoidance of doubt, shall not be prior to the Termination Date (as defined below), if not revoke

* * *

505 Montgomery Street, Suite 2000 San Francisco, California 94111-6538 Tel: +1.415.391.0600 Fax: +1.415.395.8095 www.lw.com FIRM / AFFILIATE OFFICES August 8, 2023 Austin Beijing Boston Brussels Century City Chicago Dubai Düsseldorf Frankfurt Hamburg Hong Kong Houston London Los Angeles Madrid Milan Munich New York Orange County Paris Riyadh San Diego San Francisco Seoul Shanghai Silicon Valley Si

RBNC THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT

Exhibit 10.7(b) RBNC THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN STOCK OPTION AGREEMENT Pursuant to the option grant summary tab (“Grant Notice”) on the website to which this Stock Option Agreement (this “Agreement”) is associated, RBNC Therapeutics, Inc. (the “Company”) has granted to the option holder set forth in the Grant Notice (“Participant”) an option (the “Option”) under the Company’s 20

Confidential Draft Submission No. 8 submitted to the Securities and Exchange Commission on June 30, 2023. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains str

Table of Contents Confidential Draft Submission No. 8 submitted to the Securities and Exchange Commission on June 30, 2023. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRAT

* * *

505 Montgomery Street, Suite 2000 San Francisco, California 94111-6538 Tel: +1.415.391.0600 Fax: +1.415.395.8095 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County June 30, 2023 Century City Paris Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Shanghai Hong Kong Silicon Valley Houston Singapore London Tel Aviv Los

RBNC THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN

Exhibit 10.7(a) RBNC THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN 1. Purpose. The purpose of the Plan is to advance the interests of the Company’s stockholders by enhancing the Company’s ability to attract, retain and motivate persons who make (or are expected to make) important contributions to the Company by providing such persons with equity ownership opportunities and thereby better aligning

AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT NEUMORA THERAPEUTICS, INC. September 22, 2022

Exhibit 10.1 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT NEUMORA THERAPEUTICS, INC. September 22, 2022 AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”), is made as of September 22, 2022, by and among Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), and each of the investors in the Company’s Series B Pr

AMENDED AND RESTATED CERTIFICATE OF INCORPORATION NEUMORA THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware)

Exhibit 3.1 AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF NEUMORA THERAPEUTICS, INC. (Pursuant to Sections 242 and 245 of the General Corporation Law of the State of Delaware) Neumora Therapeutics, Inc., a corporation organized and existing under and by virtue of the provisions of the General Corporation Law of the State of Delaware (the “General Corporation Law”), DOES HEREBY CERTIFY: 1. T

BYLAWS RBNC THERAPEUTICS, INC. (a Delaware corporation) Adopted as of January 16, 2020

Exhibit 3.3 BYLAWS OF RBNC THERAPEUTICS, INC. (a Delaware corporation) Adopted as of January 16, 2020 TABLE OF CONTENTS Page ARTICLE I. IDENTIFICATION; OFFICES 1 SECTION 1. NAME 1 SECTION 2. PRINCIPAL AND BUSINESS OFFICES 1 SECTION 3. REGISTERED AGENT AND OFFICE 1 SECTION 4. CORPORATE RECORDS 1 ARTICLE II. STOCKHOLDERS 1 SECTION 1. ANNUAL MEETING 1 SECTION 2. SPECIAL MEETING 1 SECTION 3. PLACE OF

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.12 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Joshua Pinto (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supers

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.11 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and John Dunlop (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement superse

RBNC THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN RESTRICTED STOCK PURCHASE AGREEMENT

Exhibit 10.7(c) RBNC THERAPEUTICS, INC. 2020 EQUITY INCENTIVE PLAN RESTRICTED STOCK PURCHASE AGREEMENT Pursuant to the award summary tab (the “Grant Notice”) on the website to which this Restricted Stock Purchase Agreement (this “Agreement”) is associated, RBNC Therapeutics, Inc., a Delaware corporation (the “Company”), has granted to the holder set forth in the Grant Notice (the “Purchaser”) the

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.10 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and Paul Berns (“Executive” and, together with the Company, the “Parties”) effective as of April 11, 2022 (the “Effective Date”). This Agreement supersed

Confidential Draft Submission No. 7 submitted to the Securities and Exchange Commission on May 2, 2023. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains stric

Table of Contents Confidential Draft Submission No. 7 submitted to the Securities and Exchange Commission on May 2, 2023. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATIO

* * *

140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Austin Milan Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh September 2, 2022 Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Shanghai Hong Kong Silicon Valley Houston Singapore London Tel Aviv Los Angeles Tokyo Madrid

Confidential Draft Submission No. 6 submitted to the Securities and Exchange Commission on September 2, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains

Table of Contents Confidential Draft Submission No. 6 submitted to the Securities and Exchange Commission on September 2, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGIS

Confidential Draft Submission No. 5 submitted to the Securities and Exchange Commission on June 10, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains str

Table of Contents Confidential Draft Submission No. 5 submitted to the Securities and Exchange Commission on June 10, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRAT

* * *

140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Austin Moscow Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh June 10, 2022 Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Shanghai Hong Kong Silicon Valley Houston Singapore London Tel Aviv Los Angeles Tokyo Madrid Was

TRANSITION AND SEPARATION AGREEMENT

Exhibit 10.23 TRANSITION AND SEPARATION AGREEMENT This Transition and Separation Agreement (the “Agreement”) by and between Lori Lyons-Williams (“Executive”) and Neumora Therapeutics, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts: A. Executive’s serv

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.25 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [ ] (“Executive” and, together with the Company, the “Parties”) effective as of April , 2022 (the “Effective Date”). This Agreement supersedes in its

Confidential Draft Submission No. 4 submitted to the Securities and Exchange Commission on May 2, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains stric

Table of Contents Confidential Draft Submission No. 4 submitted to the Securities and Exchange Commission on May 2, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATIO

NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT

Exhibit 10.24 NEUMORA THERAPEUTICS, INC. EXECUTIVE EMPLOYMENT AGREEMENT This Executive Employment Agreement (the “Agreement) is entered into between Neumora Therapeutics, Inc., a Delaware corporation f/k/a RBNC Therapeutics, Inc. (the “Company”), and [] (“Executive” and, together with the Company, the “Parties”) effective as of April , 2022 (the “Effective Date”). This Agreement supersedes in its

AMENDMENT NO. 1 TO LICENSE AGREEMENT

Exhibit 10.6(b) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. AMENDMENT NO. 1 TO LICENSE AGREEMENT This AMENDMENT NO. 1 TO LICENSE AGREEMENT (“Amendment No. 1”) is effective March 31, 2021 (the “Amendment No. 1 Effective Date”) and is ma

SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

Exhibit 10.5(c) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This Second Amendment (“Amendment”) is entered into effective as of April 9, 2019 and is made to the EXCLUSIVE LICENSE AGREEMEN

LICENSE AGREEMENT

Exhibit 10.5(a) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. LICENSE AGREEMENT This License Agreement is effective as of November 23, 2015 (the “Effective Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit pub

EXCLUSIVE LICENSE AGREEMENT FOR GCASE by and between AMGEN INC. RBNC Therapeutics, Inc. Dated as of September 10, 2021

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

Exhibit 10.5(b) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This First Amendment (“Amendment”) is entered into effective as of November 13, 2017 and is made to the EXCLUSIVE LICENSE AGREEM

Confidential Draft Submission No. 3 submitted to the Securities and Exchange Commission on February 11, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains

Table of Contents Confidential Draft Submission No. 3 submitted to the Securities and Exchange Commission on February 11, 2022. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGIS

LICENSE AGREEMENT

Exhibit 10.6(a) [***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10). Such excluded information is not material and is treated by the Registrant as private or confidential. LICENSE AGREEMENT This License Agreement (this “Agreement”) is entered into as of this 15th day of June, 2020 (the “Effective Date”), by and between Syllable Life Sciences, In

RESEARCH COLLABORATION LICENSE AGREEMENT by and between AMGEN INC. RBNC THERAPEUTICS, INC. Dated as of September 10, 2021

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

EXCLUSIVE LICENSE AGREEMENT FOR CK1d by and between AMGEN INC. RBNC Therapeutics, Inc. Dated as of September 10, 2021

[***] Certain information in this document has been excluded pursuant to Regulation S-K, Item 601(b)(10).

* * *

February 11, 2022 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Austin Moscow Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Shanghai Hong Kong Silicon Valley Houston Singapore London Tel Aviv Los Angeles Tokyo Madrid

FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

Exhibit 10.5(b) FIRST AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This First Amendment (“Amendment”) is entered into effective as of November 13, 2017 and is made to the EXCLUSIVE LICENSE AGREEMENT dated November 23, 2015 (the “License Agreement”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and BLACKTHORN THERAPEUTICS, INC., a Delaware c

SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT

Exhibit 10.5(c) SECOND AMENDMENT TO EXCLUSIVE LICENSE AGREEMENT This Second Amendment (“Amendment”) is entered into effective as of April 9, 2019 and is made to the EXCLUSIVE LICENSE AGREEMENT dated November 23, 2015 as amended on November 13, 2017 (the “Agreement”) by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI“), and BLACKTHORN THERAPEUTIC

Confidential Draft Submission No. 2 submitted to the Securities and Exchange Commission on December 22, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains

Table of Contents Confidential Draft Submission No. 2 submitted to the Securities and Exchange Commission on December 22, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confidential. Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGIS

AMENDMENT NO. 1 TO LICENSE AGREEMENT

Exhibit 10.6(b) AMENDMENT NO. 1 TO LICENSE AGREEMENT This AMENDMENT NO. 1 TO LICENSE AGREEMENT (“Amendment No. 1”) is effective March 31, 2021 (the “Amendment No. 1 Effective Date”) and is made by and between Syllable Life Sciences, Inc. (“Syllable”), and the President and Fellows of Harvard College, (“Harvard”). This Amendment No. 1 shall serve as an amendment to that certain License Agreement da

LICENSE AGREEMENT

Exhibit 10.6(a) LICENSE AGREEMENT This License Agreement (this “Agreement”) is entered into as of this 15th day of June, 2020 (the “Effective Date”), by and between Syllable Life Sciences, Inc., a corporation existing under the laws of Delaware, having a place of business at c/o Cambridge Innovation Center, 1 Broadway, 14th floor, Cambridge, MA 02142 (“Syllable”) and President and Fellows of Harva

LICENSE AGREEMENT

Exhibit 10.5(a) LICENSE AGREEMENT This License Agreement is effective as of November 23, 2015 (the “Effective Date”), by and between THE SCRIPPS RESEARCH INSTITUTE, a California nonprofit public benefit corporation (“TSRI”), and BLACKTHORN THERAPEUTICS, INC. (“Licensee”), a Delaware corporation located at 329 Oyster Point Blvd, South San Francisco, 94080. RECITALS WHEREAS, TSRI is engaged in funda

* * *

December 22, 2021 140 Scott Drive Menlo Park, California 94025 Tel: +1.650.328.4600 Fax: +1.650.463.2600 www.lw.com FIRM / AFFILIATE OFFICES Austin Moscow Beijing Munich Boston New York Brussels Orange County Century City Paris Chicago Riyadh Dubai San Diego Düsseldorf San Francisco Frankfurt Seoul Hamburg Shanghai Hong Kong Silicon Valley Houston Singapore London Tel Aviv Los Angeles Tokyo Madrid

As confidentially submitted to the Securities and Exchange Commission on November 8, 2021. This draft registration statement has not been publicly filed with the Securities and Exchange Commission and all information herein remains strictly confident

Table of Contents As confidentially submitted to the Securities and Exchange Commission on November 8, 2021.